Hospital
Diley Ridge Medical Center
Diley Ridge Medical Center was paid $6.17M by Medicaid between Jan 2018 and Dec 2024, across 109 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoDILEY RIDGE MEDICAL CENTER
CANAL WINCHESTER, OH 43110
CANAL WINCHESTER, OH 43110
33aNPI1225361181assigned 09/10/2009
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.17M
24GClaims120,462
24DCodes billed109
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#86 of 101
Median peer was paid$22.32M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,240 | $444K | |
| 2019 | 6,724 | $384K | |
| 2020 | 2,822 | $257K | |
| 2021 | 3,484 | $289K | |
| 2022 | 3,337 | $239K | |
| 2023 | 53,128 | $2.46M | |
| 2024incomplete | 43,727 | $2.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 19,301 | 17,596 | $2.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 5,720 | 4,882 | $789K |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 1,980 | 1,477 | $778K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.2% | 4,853 | 4,405 | $571K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 1,087 | 884 | $347K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 2,167 | 1,734 | $341K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 762 | 603 | $227K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 548 | 440 | $167K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 2,470 | 2,145 | $99K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 2,419 | 2,067 | $73K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 271 | 219 | $57K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 421 | 385 | $49K |
97 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 408 | $45K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 115 | $40K |
| 81513 | <1% | 218 | $34K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,095 | $29K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,223 | $26K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,159 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 798 | $13K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,469 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,454 | $11K |
| 80061 | Lipid panel | <1% | 735 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 90 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 273 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,869 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 557 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 274 | $6K |
| 10060 | <1% | 31 | $6K | |
| 72100 | <1% | 192 | $5K | |
| 73030 | <1% | 311 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 43 | $4K |
| 85027 | <1% | 839 | $4K | |
| 83735 | <1% | 1,020 | $4K | |
| 82607 | <1% | 155 | $3K | |
| 82248 | <1% | 1,572 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 41 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,275 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,580 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 600 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 20 | $2K |
| 73630 | <1% | 368 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,445 | $2K |
| 73610 | <1% | 315 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,969 | $2K |
| 81001 | <1% | 3,389 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,095 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 600 | $1K |
| 85055 | <1% | 123 | $1K | |
| 84484 | <1% | 1,585 | $1K | |
| 73130 | <1% | 294 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 536 | $1K |
| 83540 | <1% | 115 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 25 | $1K |
| 83690 | <1% | 1,676 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 33 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 66 | $1K |
| 73110 | <1% | 109 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,913 | $979.43 |
| 81025 | <1% | 2,735 | $917.94 | |
| 84702 | <1% | 355 | $911.96 | |
| 83880 | <1% | 308 | $906.68 | |
| 84439 | <1% | 66 | $851.02 | |
| 90715 | <1% | 37 | $787.30 | |
| 85610 | <1% | 231 | $765.46 | |
| 82077 | <1% | 71 | $759.83 | |
| 73502 | <1% | 14 | $732.76 | |
| 81003 | <1% | 1,298 | $655.03 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 341 | $647.69 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,418 | $644.88 |
| 82570 | <1% | 67 | $635.73 | |
| 87481 | <1% | 218 | $545.41 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 18 | $526.81 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 324 | $526.07 |
| 83605 | <1% | 442 | $509.61 | |
| 73564 | <1% | 199 | $499.23 | |
| 82805 | <1% | 25 | $445.83 | |
| 87210 | <1% | 152 | $366.90 | |
| 82728 | <1% | 19 | $305.98 | |
| 85379 | <1% | 482 | $298.33 | |
| 82043 | <1% | 48 | $287.11 | |
| 96376 | <1% | 266 | $280.31 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 789 | $269.38 |
| 83550 | <1% | 41 | $264.38 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 16 | $254.34 |
| 80076 | <1% | 26 | $243.90 | |
| 87040 | <1% | 113 | $189.23 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 41 | $175.05 |
| 85730 | <1% | 91 | $170.47 | |
| 85652 | <1% | 32 | $154.05 | |
| 84703 | <1% | 165 | $150.55 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,325 | $103.07 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,576 | $97.21 |
| 87077 | <1% | 15 | $87.74 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 398 | $73.59 |
| 87186 | <1% | 13 | $70.90 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 147 | $58.26 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 518 | $39.09 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 111 | $35.36 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 337 | $31.26 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,607 | $26.66 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 48 | $17.58 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 507 | $16.11 |
| 81015 | <1% | 27 | $6.05 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 32 | $5.49 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 184 | $5.18 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 57 | $0.09 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14 | $0.04 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPRIDAY, ANDREW (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Mount Carmel Health System | Columbus, OH | $66.65M |
| Mount Carmel Health System | Westerville, OH | $42.48M |
| Mount Carmel Health System | Grove City, OH | $14.42M |
| Mount Carmel Health System | Columbus, OH | $5.23M |
| Mount Carmel Health System | Columbus, OH | $403K |
| Mount Carmel Health System | Columbus, OH | $318K |
| Mount Carmel Health System | Grove City, OH | $180K |
| Mount Carmel Health System | New Albany, OH | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.